March 22, 2012Open Access

Effect of Alipogene Tiparvovec (AAV1-LPLS447X) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients

ACAndré C. CarpentierPreventive Cardiology FFFrédérique FrischUniversité de Sherbrooke SLSébastien M. LabbéUniversité de Sherbrooke

Structured PICO

Does intramuscular alipogene tiparvovec improve postprandial chylomicron metabolism in LPLD patients?

Population

Lipoprotein Lipase-Deficient (LPLD) patients

Intervention

Intramuscular administration of alipogene tiparvovec (AAV1-LPL S447X)

Outcome

Postprandial chylomicron metabolismsurrogate

Alipogene tiparvovec significantly improves postprandial chylomicron metabolism in patients with lipoprotein lipase deficiency.

Abstract

Intramuscular administration of alipogene tiparvovec resulted in a significant improvement of postprandial chylomicron metabolism in LPLD patients, without inducing large postprandial NEFA spillover.

Perguntar à IA

Bookmark

View Full Paper